What Is a Neoantigen Cancer Vaccine ?
Neoantigens are tumor-specific protein fragments arising from cancer-cell mutations and are absent from normal tissue. Genomic sequencing and AI-based algorithms can be used to identify patient-specific neoantigens and design personalized vaccine therapies.
GT601: An AI-Driven, Next-Generation Neoantigen Cancer Vaccine
GT601 is built on GRIT Bio's proprietary AI-assisted neoantigen discovery platform, leveraging the Company's extensive internal functional validation data and multi-omics data accumulated through TIL R&D. The neoantigen sequences selected can better achieve specific immune responses and reprogram the tumor microenvironment, thereby reducing exhausted CD8+ T cells and regulatory T cells (Tregs). GT601 holds promise for breakthroughs in the post-surgical adjuvant setting and may synergize with multiple therapeutic modalities including TIL, in vivo CAR-T, and CAR-iNKT cell therapies.
GT601
GT601 is a personalized neoantigen tumor vaccine leveraging proprietary TIL R&D data for AI model training to drive vaccine development.
Indications
Solid tumors
Technology Platform
NEOvigator® / APC‑Targeted LNP DeliveryTechnology
AI-driven Algorithms Represent All Steps of Antigen Presentation And T Cell Response
NeoAntigen Discovery and Functional Validation Platform
The platform is designed to fully recapitulate the entire process of antigen processing, presentation and recognition, as well as the resulting T-cell response, including：
Isolation and expansion of autologous antigen-presenting cells to evaluate neoantigen expression, processing, MHC binding and presentation;
Patient-derived tumor-infiltrating lymphocytes and peripheral blood mononuclear cell (PBMC)-derived T cells to evaluate T-cell recognition of presented antigens and the resulting T-cell responses.
Traditional MHC-binding prediction
CD8+ Only Focused
Prediction Success Rate: <10%
GRIT NEOvigator® Neoantigen Discovery Platform
Covers Both CD4+ & CD8+
Prediction Success Rate: ~70%
APC-Targeted LNP Delivery System
APC-targeted lipid nanoparticles are designed to combine efficient mRNA delivery with precise targeting, reduced liver uptake and scalable manufacturing.
Lipoplex (LPX)
Classic LNP
| Category | Attribute | Lipoplex (LPX) | Classic LNP (2nd Gen) | APC-Targeted LNP |
|---|---|---|---|---|
| Physicochemical | Functional Lipid | Permanently Cationic Lipid | Ionizable Lipid | Ionizable Lipid |
| Particle Size | 200~400 nm | 60~120 nm | 60~120 nm | |
| Efficacy | APC-Targeting Specificity | Yes | No | Yes |
| mRNA Delivery Efficiency | Low | High | High | |
| Safety | Biodegradability | Poor | High | High |
| Relative Toxicity | High | Low | Low | |
| Liver Leakage | Low | Very High | Low | |
| CMC | Manufacturing Scalability | Difficult | Established | Established |
| Colloidal Stability | Low | High | High | |
| Polydispersity Index | High (>0.2) | Low (<0.2) | Low (<0.2) |